Cytosplat Special Precautions

Patients with renal impairment, hepatic impairment, depressed bone marrow function, or hearing disorder.
Infection and bleeding tendency should be considered.
Some adverse effects (e.g., ototoxicity) appear to be more severe in children.
The influence of cisplatin on human reproduction has not been determined. Cisplatin therapy might have an anti-fertility effect.
Needles or intravenous sets containing aluminum parts that may come in contact with cisplatin should not be used for preparation or administration. Aluminum reacts with cisplatin, causing precipitate formation and a loss of potency.
Should not be injected with other antitumor agents.
In vitro, cisplatin has been shown to be mutagenic in bacteria.
The drug has been shown to be carcinogenic in mice and rats. It has been reported that concomitant administration of other antitumor agents may cause cardiac infarction and cerebral infarction.
Others: Cardiac abnormalities (including conduction defects and congestive heart failure) and hypercalcemia reported to occur infrequently.
Use in pregnancy & lactation: Safe use in pregnancy has not been established.
Cisplatin should not be administered to patients who are pregnant or to mothers who are breast-feeding.